Related Experiment Video

Updated: Mar 29, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.9K

Labetalol infusion in acute myocardial infarction with systemic hypertension

P G Marx, D S Reid

    British Journal of Clinical Pharmacology
    |December 5, 2015
    PubMed

    Insights

    Labetalol safely and effectively lowered high blood pressure in acute myocardial infarction patients. This treatment reduced heart rate and improved cardiac function without side effects, with all patients surviving.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Acute myocardial infarction (AMI) can present with severe hypertension.
    • Managing hypertension in AMI is crucial for patient outcomes.

    Purpose of the Study:

    • To evaluate the safety and efficacy of labetalol in patients with AMI and severe hypertension.
    • To determine the required dosage of labetalol based on patient history.

    Main Methods:

    • Fifteen patients with suspected AMI and blood pressure (BP) > 160/110 mmHg received incremental labetalol infusions.
    • Hemodynamic parameters including BP, heart rate, and cardiac index were monitored.

    Main Results:

    • Systemic BP was safely reduced to <130/90 mmHg in all patients.
    • Significant reductions in heart rate, pulmonary artery wedge pressure, cardiac index, and stroke work index were observed.
    • Labetalol dosage varied (30-440 mg), with higher doses needed for patients with pre-existing hypertension.

    Conclusions:

    • Labetalol is a safe and effective treatment for severe hypertension in AMI.
    • Individualized dosing of labetalol is necessary, particularly in patients with a history of hypertension.
    • The treatment was associated with survival in all patients and no adverse events.

    More Related Videos

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

    Published on: May 28, 2019

    9.8K
    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    4.4K

    Related Concept Videos

    Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
    1.4K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    446
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    520
    Heart Failure Drugs: &#946;-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    1.1K
    Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

    Cardiopulmonary Resuscitation IV: Pharmacological Management

    Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
    1.3K